Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

This study has been terminated.
(In a pre-planned interim analysis, OSI-774-205 met futility for efficacy with no safety concerns. As a result, the companion trial, OSI-774-206 has been stopped)
Information provided by (Responsible Party):
Astellas Pharma Inc ( OSI Pharmaceuticals ) Identifier:
First received: November 23, 2010
Last updated: July 16, 2015
Last verified: July 2015
Patients that were assigned to the oral etoposide treatment arm in protocol OSI-774-205 and either progressed while on study or discontinued due to unacceptable toxicity related to etoposide will be allowed to participate in this study to assess the safety profile of single-agent erlotinib in patients with recurrent or refractory pediatric ependymoma.

Condition Intervention Phase
Drug: Erlotinib
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open-label, Phase 2 Study of Single-agent Erlotinib for Patients With Pediatric Ependymoma Previously Treated With Oral Etoposide in Protocol OSI-774-205

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Assess safety profile of single-agent erlotinib in patients with recurrent or refractory pediatric ependymoma previously treated with oral etoposide [ Time Frame: An average of 4 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Best disease response at end of treatment with erlotinib as determined by investigator [ Time Frame: An average of 4 months ] [ Designated as safety issue: No ]
  • Median treatment duration for patients receiving erlotinib in this clinical setting [ Time Frame: An average of 4 months ] [ Designated as safety issue: No ]

Enrollment: 4
Study Start Date: April 2011
Study Completion Date: September 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Erlotinib
Patients will receive erlotinib on a 28-day treatment cycle
Drug: Erlotinib
continuous oral Erlotinib 85 mg/m2/day
Other Names:
  • Tarceva
  • OSI-774


Ages Eligible for Study:   1 Year to 21 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have been enrolled in OSI-774-205, been randomized to oral etoposide and either progressed while on study or discontinued due to unacceptable toxicity related to etoposide
  • Performance status: Lansky ≥ 50% for patients ≤ 10 years of age or younger or Karnofsky ≥ 50% for patients greater than 10 years of age
  • Patients must have recovered from any acute toxicity to any prior anti-cancer treatment
  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age, serum glutamic pyruvic transaminase (SGPT) ALT ≤ 3 x ULN
  • Serum creatinine based on age OR Creatinine Clearance/Glomerular Filtration Rate (GFR) ≥ 70 mL/min/m2
  • Patients must be neurologically stable for at least 7 days before registration
  • Patients, both males and females, with reproductive potential must agree to practice effective contraceptive measures for the duration of study drug therapy and for at least 90 days after completion of study drug therapy
  • Patients must be able to take erlotinib orally

Exclusion Criteria:

  • Taking strong/moderate CYP3A4 or CYP1A2 inhibitors/inducers ≤ 14 days before registration
  • Have received any other chemotherapy or immunotherapy to treat ependymoma after discontinuation from OSI-774-205
  • Taking proton pump inhibitors ≤ 14 days before registration
  • Participating in another investigational drug trial while on study
  • Pregnant or breast-feeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01247922

United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
United States, California
Children's Hospital of Orange County (CHOC)
Orange, California, United States, 92868
Packard Children's Hospital
Palo Alto, California, United States, 94304
United States, Colorado
The Children's Hospital Center for Cancer and Blood Disorders
Aurora, Colorado, United States, 80045
United States, District of Columbia
Children's National Medical Center -D.C. Center for Cancer and Blood Disorders
Washington, District of Columbia, United States, 20010
United States, Florida
University of Miami
Miami, Florida, United States, 33136
United States, Georgia
Emory University Children's Healthcare of Atlanta
Atlanta, Georgia, United States, 30322
United States, Minnesota
University of Minnesota - Amplatz Children's Hospital
Minneapolis, Minnesota, United States, 55455
United States, Oregon
Oregon Health & Sciences University Doernbecher Children's Hospital
Portland, Oregon, United States, 97124
United States, Pennsylvania
Childrens Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, United States, 15224
United States, Wisconsin
University of Wisconsin
Madison, Wisconsin, United States, 53705-2275
Canada, Alberta
Stollery Children's Hospital
Edmonton, Alberta, Canada, T6G 2B7
Canada, British Columbia
Children's and Women's Health Center of BC
Vancouver, British Columbia, Canada, V6H 3V4
Canada, Ontario
Hospital for Sick Children
Toronto, Ontario, Canada, M5G 1X8
United Kingdom
Birmingham Children's Hospital Oncology Department
Birmingham, United Kingdom, B4 6NH
Royal Hospital for Sick Children
Glasgow, United Kingdom, G3 8SJ
Paediatric Oncology and Haematology Offices,
Leeds, United Kingdom, LS1 3EX
Alder Hey Children's NHS Foundation Trust
Liverpool, United Kingdom, L12 1AP
Royal Manchester Children's Hospital Ward 84
Manchester, United Kingdom, M13 9W2
University of Nottingham
Nottingham, United Kingdom, NG7 2UH
Royal Marsden Hospital
Sutton, United Kingdom, SM2 5pt
Sponsors and Collaborators
OSI Pharmaceuticals
Study Director: Medical Monitor Astellas Pharma Global Development
  More Information

Additional Information:
No publications provided

Responsible Party: Astellas Pharma Inc ( OSI Pharmaceuticals ) Identifier: NCT01247922     History of Changes
Other Study ID Numbers: OSI-774-206, 2010-023478-38
Study First Received: November 23, 2010
Last Updated: July 16, 2015
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Astellas Pharma Inc:
Pediatric Ependymoma

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors processed this record on November 25, 2015